Literature DB >> 7450397

Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.

D Vuitton, J P Miguet, G Camelot, C Delafin, C Joanne, P Bechtel, M Gillet, P Carayon.   

Abstract

The aim of this study was to look for correlations between the metabolic clearance rate of antipyrine and (a) the concentration of cytochrome P-450, and (b) the NADPH cytochrome c reductase, aminopyrine demethylase, and aniline hydroxylase activities in the liver microsomes of 20 patients without liver diseases. The results confirmed interindividual differences in the values of in vivo and in vitro assessments of hepatic drug metabolism. No significant correlation appeared in this group of patients between the metabolic clearance rate of antipyrine and the microsomal amount of cytochrome P-450, whereas the metabolic clearance rate of antipyrine exhibited a significant relationship to the NADPH cytochrome c reductase (p < 0.05), aminopyrine demethylase (p < 0.05), and aniline hydroxylase (p < 0.02) activities. These results suggest that the metabolic clearance rate of antipyrine: (a) is not strictly related to the amount of cytochrome P-450 in hepatic microsomes; and (b) although significantly related to the activity of hepatic drug-metabolizing enzymes, does not have a predictive value to assess the enzyme equipment of liver microsomes in a given normal subject.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7450397

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  4 in total

1.  Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity.

Authors:  H Kraul; J Truckenbrodt; A Huster; R Töpfer; A Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Assessment of oxidative metabolism in adults with hepatocellular carcinoma in the Sudan.

Authors:  M M Homeida; T K Daneshmend; E M Ali; A G Yousif-Elkadaru; B M Arbab
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

Review 3.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

4.  Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis.

Authors:  J P Miguet; D Vuitton; J P Deschamps; H Allemand; C Joanne; P Bechtel; P Carayon
Journal:  Dig Dis Sci       Date:  1981-08       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.